IBA – DATA CONCERNING TRANSPARENCY
Heading II of the law of May 2, 2007 and the Royal Decree of February 14, 2008
Louvain-la-Neuve, Belgium, December 3, 2018 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, communicates today the basic and additional data as per Article 15 §1 al.1 of the Transparency Law, following its capital increase (further to exercises of stock options) dated November 28, 2018.
Communication of the basic data as per Article 15 §1 al.1 of the Law
Communication of the additional data as per Article 15 §1 al.2 of the Law
Statutory thresholds as per Article 18 of the Law
The applicable thresholds as follows: three percent, five percent, ten percent, fifteen percent and so on by brackets of five percent
IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, considered to be the most advanced form of radiation therapy available today. IBA’s proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room solutions. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry. Headquartered in Belgium and employing about 1,500 people worldwide, IBA has installed systems across the world.
IBA is listed on the pan-European stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com
For further information, please contact:
+32 10 203 924